Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 May;224(1):1-4.
doi: 10.1002/path.2884. Epub 2011 Mar 22.

Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma

Affiliations
Comment

Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma

Ie-Ming Shih et al. J Pathol. 2011 May.

Abstract

Uterine carcinoma is composed mainly of two distinct types: serous and endometrioid. Uterine serous carcinoma, while not as common as endometrioid carcinoma, is a highly aggressive disease and is associated with high mortality. Although the molecular genetic alterations of uterine endometrioid carcinoma have been well established, molecular genetic changes in uterine serous carcinoma are largely unclear. Two recent papers have analysed PPP2R1A mutations among different types of gynaecological neoplasia. Both studies report a surprisingly high frequency of somatic mutations of PPP2R1A in uterine serous carcinomas. PPP2R1A encodes a scaffolding subunit of a major serine/threonine phosphatase, protein phosphatase 2A (PP2A), which plays a critical role in diverse cellular functions, including negative regulation of cellular proliferation and potential tumour suppression. As PPP2R1A is essential for the phosphatase activity of PP2A, this observation should create a new research road map toward elucidating how PPP2R1A mutations and alterations of the PP2A pathway contribute to the pathogenesis of uterine serous carcinoma.

PubMed Disclaimer

Comment on

  • Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
    McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, Mes-Masson AM; Australian Ovarian Cancer Study Group; Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, Huntsman DG. McConechy MK, et al. J Pathol. 2011 Apr;223(5):567-73. doi: 10.1002/path.2848. Epub 2011 Mar 7. J Pathol. 2011. PMID: 21381030

Substances